Q4 2024 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2025-02-14 · accession 0001172661-25-001157
$212.2M
Reported value
26
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $17.7M | 8.32% | 505,007 | Common | SHARED |
| 23282W605 | CYTK | CYTOKINETICS INC | $16.9M | 7.98% | 360,000 | Common | SHARED |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $15.1M | 7.13% | 1,787,003 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $14.4M | 6.78% | 750,000 | Common | SHARED |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $13.9M | 6.55% | 1,055,000 | Common | SHARED |
| 00370M103 | ABVX | ABIVAX SA | $12.1M | 5.69% | 1,648,523 | Common | SHARED |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $11.0M | 5.18% | 860,000 | Common | SHARED |
| 64135M105 | NGNE | NEUROGENE INC | $10.1M | 4.77% | 442,761 | Common | SHARED |
| 30052C107 | EOLS | EVOLUS INC | $9.9M | 4.66% | 895,524 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $9.6M | 4.53% | 245,272 | Common | SHARED |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $8.7M | 4.11% | 10,980,000 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $7.9M | 3.73% | 3,170,194 | Common | SHARED |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $7.1M | 3.33% | 3,009,392 | Common | SHARED |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $6.9M | 3.25% | 322,380 | Common | SHARED |
| N5749R100 | 2GH | MERUS N V | $6.6M | 3.13% | 158,092 | Common | SHARED |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $6.0M | 2.83% | 275,000 | Common | SHARED |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $5.3M | 2.47% | 500,000 | Common | SHARED |
| 91678A107 | UPB | UPSTREAM BIO INC | $4.9M | 2.32% | 300,000 | Common | SHARED |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $4.9M | 2.32% | 4,683,711 | Common | SHARED |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $4.7M | 2.21% | 826,751 | Common | SHARED |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $4.4M | 2.09% | 228,803 | Common | SHARED |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $4.0M | 1.90% | 1,150,000 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $3.0M | 1.44% | 621,894 | Common | SHARED |
| 74346M406 | PMNEUR | PROMIS NEUROSCIENCES INC | $2.5M | 1.18% | 2,645,128 | Common | SHARED |
| 68404V209 | OPTNUSD | OPTINOSE INC | $2.5M | 1.17% | 370,269 | Common | SHARED |
| M96088105 | URGN | UROGEN PHARMA LTD | $2.0M | 0.94% | 187,843 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.